Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
Couzin
Jennifer
J
D001319:Authorship; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D016208:Databases, Factual; D004345:Drug Industry; D035081:Editorial Policies; D006801:Humans; D020407:Internet; D007783:Lactones / Q000009:adverse effects*; D009316:National Institutes of Health (U.S.); D010506:Periodicals as Topic / Q000592:standards; D011643:Publishing / Q000592:standards*; D012042:Registries; D013450:Sulfones / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D014481:United States
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib